HCV Declines Level Off in HIV+ Men Who Have Sex With Men HCV Declines Level Off in HIV+ Men Who Have Sex With Men
The incidence of hepatitis C virus infection among HIV-positive men who have sex with men in the Netherlands fell once direct-acting antivirals became universally available in 2015, new findings show.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
[10-22-2015] The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause severe liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Informaci & oacute;n actualizada sobre la interacci & oacute;n entre el medicamento Victrelis (boceprevir) y ciertos medicamentos reforzados inhibidores de la proteasa del VIH
El 26 de abril del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que, en estos momentos, no se recomienda tomar conjuntamente Victrelis (boceprevir), un inhibidor de la proteasa del virus de la hepatitis C (VHC) junto con ciertos inhibidores de la proteasa del virus de la inmunodeficiencia humana VIH reforzados con ritonavir, por la posibilidad de reducir la eficacia de los medicamentos, lo que puede desencadenar el aumento del VHC o VIH en la sangre (carga viral). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 6, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Nobel Prize reflects perseverance in scientific research
(Mary Ann Liebert, Inc./Genetic Engineering News) New Rochelle, NY, December 21, 2020--The 2020 Nobel Prize in Physiology or Medicine went to three researchers for their discovery of hepatitis C virus (HCV). The undying perseverance that it took to find and cure this elusive virus (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Kidney Transplant Outcomes Similar With Hep C+ Donors
FRIDAY, Dec. 18, 2020 -- Recipients of kidneys from donors infected with hepatitis C virus (HCV) have similar kidney allograft function and probability of rejection in the first year after transplantation as those who receive kidneys from donors... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

One-Year Transplant Outcomes Similar With Kidneys From HCV+, HCV- Donors One-Year Transplant Outcomes Similar With Kidneys From HCV+, HCV- Donors
Outcomes for renal transplants from hepatitis C virus (HCV)-infected donors to HCV-negative recipients are similar to those for HCV-negative patients who receive kidneys from donors without HCV, according to a one-year follow-up study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 16, 2020 Category: Surgery Tags: Nephrology News Source Type: news

New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

One-year kidney allograft outcomes do not differ by hepatitis C status of donor
(National Kidney Foundation) Study published in AJKD shows that kidney allograft outcomes one year post-transplantation in hepatitis C virus (HCV)-negative recipients do not differ by the HCV status of the donor. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 14, 2020 Category: Infectious Diseases Source Type: news

Nobel Laureates on their Hunt for the Cure Nobel Laureates on their Hunt for the Cure
The 2020 Nobel Prize in Medicine is awarded to three scientists who discovered hepatitis C, an RNA virus that was curbed by common-sense public health measures before new antivirals could save lives.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2020 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Cannabis Use and Diabetes Risk in Chronic HCV Infection Cannabis Use and Diabetes Risk in Chronic HCV Infection
This study suggests a potential protective effect of cannabis on the risk of diabetes in patients with chronic hepatitis C. What might be the mechanism behind this beneficial effect?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Hep C Testing, Identification Plummet During COVID-19
TUESDAY, Dec. 8, 2020 -- The COVID-19 systematic emergency response has led to a decrease in hepatitis C virus (HCV) testing and identification, according to a study published online Nov. 22 in the Journal of Primary Care& Community... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Violence and hepatitis C transmission in prison-a modified social ecological model - Sazzad HMS, McCredie L, Treloar C, Lloyd AR, Lafferty L.
BACKGROUND: Transmission of hepatitis C virus (HCV) among the prisoner population is most frequently associated with sharing of non-sterile injecting equipment. Other blood-to-blood contacts such as tattooing and physical violence are also common in the... (Source: SafetyLit)
Source: SafetyLit - December 5, 2020 Category: International Medicine & Public Health Tags: Violence and Weapons Issues Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

COVID-19 pandemic responsible for decrease in hepatitis C testing
(Boston Medical Center) New research from Boston Medical Center finds that the COVID-19 emergency systemic changes made to decrease in-person visits during the pandemic have led to a decrease in hospital-wide Hepatitis C (HCV) testing by 50 percent, and a reduction in new HCV diagnoses by more than 60 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2020 Category: International Medicine & Public Health Source Type: news

Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many Infants With Hep C-Positive Moms Not Screened for HCV
WEDNESDAY, Nov. 25, 2020 -- Less than one-third of infants born to mothers with hepatitis C virus infection (HCV+) receive appropriate HCV follow-up testing, according to a study presented at The Liver Meeting, the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Health and care heroes honoured in parliamentary awards
Doctors and nurses working to combat Hepatitis C in the homeless during the pandemic, the team behind the UK ’s first virtual reality lung rehabilitation programme launched this year and the research team working on the COVID-19 vaccine have all been recognised in the regional round of the NHS parliamentary awards. (Source: NHS Networks)
Source: NHS Networks - November 24, 2020 Category: UK Health Source Type: news

Opt-Out Policy Increased HIV/HCV Testing Opt-Out Policy Increased HIV/HCV Testing
Bundled opt-out HIV/hepatitis C virus (HCV) testing increased the percentage of syringe service program (SSP) clients who received HIV and HCV rapid tests at enrollment into the program.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2020 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Vanquishing Hepatitis C: A Remarkable Success Story Vanquishing Hepatitis C: A Remarkable Success Story
A look back at one of the singular achievements in medical research of the past 25 years, and what improvements are still to come.Medscape Gastroenterology (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 17, 2020 Category: Transplant Surgery Tags: Gastroenterology Commentary Source Type: news

X-ray study explores potential of hepatitis C drugs to treat COVID-19
(DOE/Oak Ridge National Laboratory) Researchers at the Department of Energy's Oak Ridge National Laboratory investigated the binding properties of several hepatitis C drugs to determine how well they inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce. Inhibiting, or blocking, the protease from functioning is vital to stopping the virus from spreading in patients with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 16, 2020 Category: Infectious Diseases Source Type: news

HCV Care Can Learn a Thing or Two From the HIV Experience HCV Care Can Learn a Thing or Two From the HIV Experience
Patients with hepatitis C virus and HIV share some of the same treatment challenges, suggesting similar care models can be used for these conditions to improve rates of treatment adherence and success.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 15, 2020 Category: Gastroenterology Tags: Nursing News Source Type: news

Researchers discover enzyme suppressing immune response to viral infections
(University of Missouri-Columbia) Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections. These viruses remain a serious health threat, but researchers from the University of Missouri School of Medicine have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Basel, 22 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea ’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In...
Source: Roche Media News - October 22, 2020 Category: Pharmaceuticals Source Type: news

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Basel, 22 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea ’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In...
Source: Roche Investor Update - October 22, 2020 Category: Pharmaceuticals Source Type: news

A promising discovery could lead to better treatment for Hepatitis C
(Institut national de la recherche scientifique - INRS) Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians. Antivirals exist but are expensive and not readily available in developing countries, where the disease is most prevalent. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2020 Category: Infectious Diseases Source Type: news

Virologists: What Do They Do?
Virologists are highly skilled medical experts who manage the diagnosis, treatment, and prevention of infectious diseases such as hepatitis C, Ebola, and now COVID-19. Learn more about them. (Source: WebMD Health)
Source: WebMD Health - October 20, 2020 Category: Consumer Health News Source Type: news

Glecaprevir and Pibrentasvir Aid HCV D+/R − Kidney Transplants
WEDNESDAY, Oct. 14, 2020 -- By treating or preventing infection, glecaprevir and pibrentasvir (G/P) regimens are promising for increasing access to the transplantation of kidneys from hepatitis C virus (HCV)-positive donors to HCV-negative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 14, 2020 Category: Pharmaceuticals Source Type: news

Nobel Prize for Chemistry Awarded for ‘Genome Scissors’
(STOCKHOLM) — French scientist Emmanuelle Charpentier and American Jennifer A. Doudna have won the Nobel Prize in chemistry for developing a method of genome editing likened to “molecular scissors” that offer the promise of one day curing genetic diseases. The recipients were announced Wednesday in Stockholm by the Royal Swedish Academy of Sciences. “There is enormous power in this genetic tool, which affects us all,” said Claes Gustafsson, chair of the Nobel Committee for Chemistry. “It has not only revolutionised basic science, but also resulted in innovative crops and will lead to gro...
Source: TIME: Science - October 7, 2020 Category: Science Authors: Associated Press Tags: Uncategorized Chemistry News Desk overnight wire Source Type: news

American Andrea Ghez and 2 Others Win Nobel Prize in Physics
(STOCKHOLM) — Three scientists won this year’s Nobel Prize in physics Tuesday for advancing our understanding of black holes, the all-consuming monsters that lurk in the darkest parts of the universe. Briton Roger Penrose received half of this year’s prize “for the discovery that black hole formation is a robust prediction of the general theory of relativity,” the Nobel Committee said. German Reinhard Genzel and American Andrea Ghez received the second half of the prize “for the discovery of a supermassive compact object at the center of our galaxy.” The prize celebrates “one...
Source: TIME: Science - October 6, 2020 Category: Science Authors: DAVID KEYTON and SETH BORENSTEIN /AP Tags: Uncategorized overnight Space wire Source Type: news

New research supports sofosbuvir in combination with other antivirals for COVID-19
(Columbia University School of Engineering and Applied Science) Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA--Sofosbuvir/Velpatasvir--in combination with other drugs in COVID-19 clinical trials. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2020 Category: International Medicine & Public Health Source Type: news

Virologist Michael Houghton Is One Of The 2020 Nobel Prize In Medicine Recipients
Researchers Harvey J. Alter, Charles M. Rice and Michael Houghton were awarded the 2020 Nobel Prize in Physiology or Medicine for the discovery of the Hepatitis C virus, a breakthrough that the Nobel Assembly described as a “decisive contribution.” (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 5, 2020 Category: Pharmaceuticals Authors: Farah Qaiser, Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science Source Type: news

2020 Nobel Prize in Medicine Goes to Scientists Who Discovered Hepatitis C
Harvey J. Alter, Michael Houghton and Charles M. Rice were jointly honored for their decisive contribution to the fight against blood-borne hepatitis, a major global health problem. (Source: NYT Health)
Source: NYT Health - October 5, 2020 Category: Consumer Health News Authors: Katherine J. Wu and Daniel Victor Tags: your-feed-science Nobel Prizes Medicine and Health Hepatitis Norway Alter, Harvey James Rice, Charles M Houghton, Michael Source Type: news

Three Scientists Share Nobel Prize for Hepatitis C Research
MONDAY, Oct. 5, 2020 -- Two U.S. researchers and a British scientist have been awarded the 2020 Nobel Prize in physiology or medicine for major contributions to the fight against blood-borne hepatitis. Hepatitis C causes 400,000 deaths worldwide... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 5, 2020 Category: Pharmaceuticals Source Type: news

Three Share Nobel Prize for Hepatitis C Research
The three recipients are: Harvey Alter, a clinical scientist at a U.S. National Institutes of Health blood bank; Charles Rice, of the Washington University in St. Louis; and British-born virologist Michael Houghton. (Source: WebMD Health)
Source: WebMD Health - October 5, 2020 Category: Consumer Health News Source Type: news

Nobel prize in medicine awarded to US-UK trio for work on hepatitis C
Harvey Alter, Michael Houghton, Charles Rice share 10m Swedish kronor prizeTwo Americans and a British scientist have been awarded the Nobel prize in medicine for their groundbreaking work on blood-borne hepatitis, a health problem that causes cirrhosis and liver cancer around the world.Harvey J Alter at the US National Institutes of Health in Maryland, Charles M Rice from Rockefeller University in New York, and Michael Houghton, a British virologist at the University of Alberta in Canada, were honoured for their joint discovery of the hepatitis C virus, a major cause of liver disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 5, 2020 Category: Science Authors: Ian Sample Science editor Tags: Nobel prizes Science UK news Medicine Science prizes People in science Nobel prize in literature Awards and prizes Source Type: news

Researchers Who Discovered Hepatitis C Earn Nobel Prize
Harvey Alter, Michael Houghton, and Charles Rice share the Physiology or Medicine award for their contributions to identifying the virus and demonstrating that it was responsible for hepatitis among... (Source: The Scientist)
Source: The Scientist - October 5, 2020 Category: Science Tags: News & Opinion Source Type: news

Discoverers of hepatitis C virus win Nobel medicine prize
Honour given special resonance in year when world is gripped by coronavirus pandemic (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 5, 2020 Category: Pharmaceuticals Source Type: news

Trio Awarded Nobel Prize in Medicine for Discovering Hep C Virus Trio Awarded Nobel Prize in Medicine for Discovering Hep C Virus
The achievement by two Americans and a British-born scientist rapidly led to medications, blood tests, a cure, and'hopes of eradicating hepatitis C virus from the world population. 'Medscape Medical News (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 5, 2020 Category: Universities & Medical Training Tags: Infectious Diseases News Alert Source Type: news

Nobel Prize In Medicine Awarded To Trio Of Scientists Who Discovered Hepatitis C Virus
The separate discoveries made by the scientists helped create blood tests and medicines to treat the blood-borne, chronic disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 5, 2020 Category: Pharmaceuticals Authors: Siladitya Ray, Forbes Staff Tags: Business /business Science /science Healthcare /healthcare Innovation /innovation Breaking breaking-news Source Type: news

3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news

NIH intramural researcher Dr. Harvey Alter wins 2020 Nobel Prize in Physiology or Medicine
Dr. Alter honored for his contributions to the discovery of the hepatitis C virus. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - October 5, 2020 Category: American Health Source Type: news

Nobel Prize for Medicine goes to Hepatitis C discovery
The virus is a major cause of liver cancer and can lead to people needing a liver transplant. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 5, 2020 Category: Consumer Health News Source Type: news

Health Highlights: Oct. 5, 2020
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Three Scientists Share Nobel Prize for Hepatitis C Research Two U.S. researchers and a British scientist have been awarded the 2020 Nobel Prize... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2020 Category: General Medicine Source Type: news

3 Scientists Win Nobel Prize For Hepatitis C Virus Discovery
The scientists' work led to a test to protect blood transfusion recipients from hepatitis C and drugs to treat the infection that have saved millions of lives, according to the Nobel Assembly.(Image credit: Markus Marcetic/Courtesy of Myntverket (Swedish Mint)) (Source: NPR Health and Science)
Source: NPR Health and Science - October 5, 2020 Category: Consumer Health News Authors: Rob Stein Source Type: news

University of Alberta researcher among 3 awarded Nobel Prize in medicine for hepatitis C discovery
British scientist Michael Houghton, who works at the University of Alberta, and Americans Harvey J. Alter and Charles M. Rice were awarded the Nobel Prize in Medicine on Monday for the discovery of the hepatitis C virus. (Source: CBC | Health)
Source: CBC | Health - October 5, 2020 Category: Consumer Health News Tags: News/Health Source Type: news

Nobel Prize for Discovering Hepatitis C Virus
Trio Awarded Nobel Prize in Medicine for Discovering Hepatitis C Virus (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 5, 2020 Category: General Medicine Source Type: news

NIH intramural researcher Dr. Harvey Alter wins 2020 Nobel Prize in Physiology or Medicine
(NIH/Office of the Director) National Institutes of Health intramural researcher Harvey J. Alter, M.D., has won the 2020 Nobel Prize in Physiology or Medicine for his contributions to the discovery of the hepatitis C virus. Dr. Alter is a Senior Scholar at the NIH Clinical Center's Department of Transfusion Medicine and shares the award with Michael Houghton, Ph.D., University of Alberta, Canada, and Charles M. Rice, Ph.D., Rockefeller University, New York City. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2020 Category: Biology Source Type: news

University of Alberta virologist awarded Nobel Prize in Physiology or Medicine
(University of Alberta Faculty of Medicine& Dentistry) Michael Houghton was awarded the 2020 Nobel Prize in Physiology or Medicine today in recognition of his discovery of the hepatitis C (HCV) virus.His discovery with colleagues Qui-Lim Choo and George Kuo in 1989 opened a new field of viral hepatitis research that led to improved blood safety, and hepatitis C treatment to the point where the viral infection can now be cured in virtually all patients. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 5, 2020 Category: Infectious Diseases Source Type: news

After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO
Two-year-old Aligos Therapeutics Inc. is seeking a $100 million initial public offering to help take its experimental chronic hepatitis B drugs into clinical trials. The South San Francisco company is the work of much of the executive team that translated $74 million in investments for hepatitis C-focused Alios BioPharma Inc. of South San Francisco into a $1.75 billion cash deal in 2014 with Johnson& Johnson's (NYSE: JNJ) Janssen Pharmaceutical unit. Janssen ultimately dumped Alios' oral drug,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 28, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news